Rheumatoid Arthritis in Pregnancy and Lactation

Dr Neeraj Manikath , claude.ai

Abstract

Rheumatoid arthritis (RA) management during pregnancy and lactation presents unique challenges requiring careful consideration of disease activity, fetal safety, and maternal well-being. This review provides evidence-based strategies for optimizing outcomes in this special population, emphasizing medication safety profiles, disease monitoring, and multidisciplinary care coordination.

Introduction

Rheumatoid arthritis affects approximately 1% of the global population, with peak incidence in women of childbearing age. The intersection of RA and pregnancy creates a complex clinical scenario where the internist must balance disease control against potential teratogenic risks, navigate the paradoxical improvement many patients experience during gestation, and prepare for the frequent postpartum flares that characterize this condition. Understanding the physiological and immunological changes underlying these patterns is essential for providing optimal care.

Pathophysiology: The Pregnancy Paradox

The remarkable improvement of RA during pregnancy, observed in 50-75% of patients, represents one of medicine's most fascinating immunological phenomena. This amelioration likely results from the shift toward Th2-dominant immunity, increased cortisol production, rising levels of pregnancy-associated hormones including estrogen and progesterone, and the presence of fetal microchimerism modulating maternal immune responses. Conversely, the postpartum period witnesses a rapid return to Th1 dominance, precipitating flares in up to 90% of patients within three to six months of delivery.

Pearl: Patients with RF-negative, anti-CCP-negative disease are less likely to experience pregnancy-induced improvement, helping stratify expectations during preconception counseling.

Preconception Counseling: The Foundation of Success

The preconception visit represents the single most important intervention in managing RA during pregnancy. This encounter should occur at least three to six months before planned conception, allowing adequate time for medication adjustment and disease optimization.

Step 1: Assess Disease Activity and Prognosis

Begin with comprehensive disease activity assessment using validated instruments. The DAS28 (Disease Activity Score in 28 joints) or CDAI (Clinical Disease Activity Index) provide objective metrics. Ideally, patients should achieve low disease activity or remission for at least three months before conception. Active disease at conception increases risks of preterm birth, low birth weight, and preeclampsia.

Document baseline inflammatory markers (ESR, CRP), autoantibody status (RF, anti-CCP), and assess for extra-articular manifestations including interstitial lung disease and cardiac involvement. Echocardiography should be considered in patients with longstanding disease or cardiovascular risk factors.

Oyster: Anti-Ro/SSA and anti-La/SSB antibodies, though more common in Sjögren's syndrome and lupus, can occur in RA patients and confer risk of neonatal lupus and congenital heart block. Screen all RA patients planning pregnancy for these antibodies.

Step 2: Optimize the Medication Regimen

This critical step requires systematic review of all medications with strategic substitutions based on safety profiles.

Medications to STOP before conception:

• Methotrexate: Discontinue at least three months before conception (both partners if male is taking it). Folate supplementation at 5 mg daily should continue through conception and pregnancy given methotrexate's folate antagonism.
• Leflunomide: Requires cholestyramine washout protocol (8 grams three times daily for 11 days) or activated charcoal. Verify plasma levels below 0.02 mg/L before attempting conception.
• Mycophenolate: Stop at least six weeks before conception; severe teratogen causing characteristic craniofacial and limb abnormalities.
• JAK inhibitors (tofacitinib, baricitinib): Limited human data necessitates discontinuation before conception.
• Cyclophosphamide: Teratogenic and should be avoided.

Medications COMPATIBLE with pregnancy:

• Hydroxychloroquine: Safe throughout pregnancy and lactation. Emerging evidence suggests protective effects against pregnancy complications. Continue without interruption.
• Sulfasalazine: Compatible but increase folate to 2-5 mg daily as sulfasalazine interferes with folate metabolism. Monitor for neonatal kernicterus theoretically, though risk appears minimal with modern dosing.
• Azathioprine: Safe at doses up to 2 mg/kg/day. Well-established safety profile across rheumatology and gastroenterology literature.
• Glucocorticoids: Prednisone ≤20 mg daily is compatible. Prednisone is metabolized by placental 11β-hydroxysteroid dehydrogenase, limiting fetal exposure to approximately 10% of maternal dose. Minimize dose when possible due to associations with gestational diabetes, preeclampsia, and premature rupture of membranes.

The Biologic Conundrum:

• TNF inhibitors: Certolizumab pegol is the preferred agent given its unique pegylated Fab fragment structure lacking an Fc portion, resulting in minimal placental transfer. Infliximab and adalimumab, being IgG1 antibodies, undergo active placental transport especially after 20 weeks gestation. Traditional approach involves discontinuation in the third trimester (week 20-30 depending on agent) to minimize neonatal exposure, though emerging evidence suggests continuation may be safe in some patients.
• Etanercept: As an IgG1 fusion protein, crosses placenta less than monoclonal antibodies but more than certolizumab.
• Rituximab: B-cell depletion in neonates reported; avoid during pregnancy unless absolutely essential for severe disease.
• Abatacept, tocilizumab, anakinra: Limited data; generally avoided.

Hack: Create a "pregnancy medication card" for patients listing compatible and incompatible medications with planned transition dates. This empowers patients and ensures all providers are aligned.

Step 3: Address Comorbidities and Complications

Screen for and optimize management of comorbid conditions that complicate both RA and pregnancy. These include hypertension, diabetes, obesity, and antiphospholipid antibodies. Patients with RA have increased cardiovascular risk; consider low-dose aspirin 81-150 mg daily starting at 12-16 weeks gestation for preeclampsia prophylaxis, particularly in patients with additional risk factors.

Pregnancy Management: A Trimester-by-Trimester Approach

First Trimester: Confirmation and Consolidation

Once pregnancy is confirmed, conduct immediate medication review. This is the final opportunity to discontinue any Category X medications that may have been inadvertently continued. Reassess disease activity and adjust compatible medications as needed.

Counsel patients about expected disease course. Many patients experience their first improvement during weeks 10-15 as pregnancy-related immunological changes take effect. However, the first trimester can also witness continued active disease requiring therapeutic intervention.

Initiate folate supplementation if not already prescribed. All RA patients should receive at least 1-2 mg daily; those recently transitioned from methotrexate should receive 5 mg daily.

Pearl: Morning stiffness duration often improves more dramatically than joint counts during pregnancy, making it a particularly useful monitoring parameter.

Second Trimester: The Sweet Spot

Most patients experience optimal disease control during the second trimester. This represents the ideal time for comprehensive fetal assessment including detailed anatomy ultrasound at 18-20 weeks.

For patients on TNF inhibitors, decisions regarding continuation versus discontinuation should occur before 20 weeks when active placental transport intensifies. Individualize based on disease severity, previous flare history, and patient preferences. Patients with severe, erosive disease who have failed multiple agents may warrant continued therapy throughout pregnancy after careful discussion of limited but reassuring available data.

Monitor disease activity monthly using clinical assessment. Laboratory markers including ESR become less reliable during pregnancy due to physiological increases, while CRP remains more specific for inflammatory activity.

Hack: Use a pregnancy-modified DAS28 that omits ESR and weights clinical parameters more heavily for disease activity assessment during gestation.

Third Trimester: Preparation for Delivery and Postpartum

Continue disease activity monitoring. Some patients experience disease recrudescence in the third trimester, potentially requiring dose adjustments of compatible medications.

Discuss delivery planning with obstetrics colleagues. Most RA patients can deliver vaginally unless obstetric indications mandate cesarean section. However, patients with severe hip disease, cervical spine involvement (particularly atlantoaxial subluxation), or significant temporomandibular joint disease require specialized anesthetic evaluation.

Oyster: Approximately 2% of RA patients develop cervical spine instability. Patients with longstanding, erosive disease undergoing cesarean section or requiring endotracheal intubation should have flexion/extension cervical spine radiographs to assess for atlantoaxial subluxation before anesthesia.

Develop a detailed postpartum medication plan. This is crucial because the chaotic early postpartum period often leads to medication confusion and missed opportunities for flare prevention.

The Critical Postpartum Period: Prevention and Management of Flares

The postpartum period represents the highest risk time for RA flares. A systematic approach to this vulnerable period can prevent significant morbidity.

Step 1: Immediate Postpartum Medication Restart

Restart all pregnancy-compatible medications immediately after delivery. For patients who discontinued TNF inhibitors during pregnancy, resume these agents within days of delivery, particularly if not breastfeeding.

Patients who were in remission on methotrexate before pregnancy face a dilemma if breastfeeding. While traditional teaching deems methotrexate incompatible with lactation, recent evidence suggests weekly dosing results in minimal breast milk transfer. However, most experts continue to recommend avoiding methotrexate during breastfeeding, necessitating alternative strategies.

Pearl: Consider bridging the early postpartum period with a short course of low-dose prednisone (5-10 mg daily for 4-6 weeks) in high-risk patients (those with severe disease requiring methotrexate pre-pregnancy or those who flared despite pregnancy-compatible medications during gestation).

Step 2: Close Monitoring

Schedule the first postpartum rheumatology visit within 2-4 weeks of delivery, earlier if symptoms emerge. Many flares occur within the first six weeks postpartum. Telephone or telemedicine check-ins at weeks 1-2 can identify evolving flares before they become severe.

Step 3: Lactation Counseling

Provide evidence-based lactation counseling incorporating patient preferences. The decision to breastfeed involves weighing benefits of breast milk against potential need for highly effective but lactation-incompatible medications.

Medications COMPATIBLE with lactation:

• Hydroxychloroquine: Safe, minimal transfer
• Sulfasalazine: Safe, minimal transfer
• Prednisone: Compatible at doses ≤20 mg daily; some recommend timing breastfeeding before dose or waiting 4 hours after dose to minimize infant exposure, though this is probably unnecessary at standard doses
• Azathioprine: Compatible based on extensive inflammatory bowel disease literature
• NSAIDs: Ibuprofen is preferred; avoid naproxen and aspirin due to longer half-lives
• TNF inhibitors: All are likely compatible given large molecular weight limiting breast milk transfer and degradation in infant GI tract. Best data exist for certolizumab, infliximab, and adalimumab.

Medications to AVOID during lactation:

• Methotrexate: Traditional teaching recommends avoidance
• Leflunomide: Contraindicated
• Cyclophosphamide: Contraindicated
• JAK inhibitors: Avoid due to limited data

Hack: For patients requiring methotrexate who wish to breastfeed, consider "pump and dump" for 24 hours after the weekly dose, allowing breastfeeding for the remaining six days. While not universally endorsed, this represents a potential compromise for highly motivated patients, though data supporting this approach remain limited.

Special Scenarios and Complications

The Patient with Active Disease Despite Pregnancy-Compatible Medications

Some patients maintain active disease despite optimal use of pregnancy-compatible agents. This scenario requires individualized decision-making incorporating disease severity, gestational age, previous treatment responses, and patient values.

Options include:

1. Dose optimization of current agents (e.g., increasing prednisone, though mindful of side effects)
2. Addition of certolizumab pegol if not already prescribed
3. Short-term higher-dose prednisone with rapid taper
4. For refractory severe disease, continuation or initiation of other TNF inhibitors after extensive counseling
5. In extreme cases after 32-34 weeks gestation, consideration of early delivery with neonatal intensive care unit availability

Pearl: Intra-articular or intramuscular corticosteroid injections provide effective rescue therapy for articular flares without systemic medication escalation.

The Patient with Antiphospholipid Antibodies

Approximately 15-20% of RA patients have antiphospholipid antibodies, conferring thrombotic and obstetric risks. All RA patients should be screened for lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies before or during early pregnancy.

Patients meeting criteria for antiphospholipid syndrome require prophylactic anticoagulation (typically low-molecular-weight heparin) and low-dose aspirin throughout pregnancy and the postpartum period. Coordinate care with maternal-fetal medicine specialists.

Contraception Planning

Discuss contraception at postpartum and routine visits. Highly effective contraception allows optimal disease control before subsequent pregnancies. All hormonal and barrier methods are compatible with RA medications. Copper and levonorgestrel intrauterine devices represent excellent options providing long-term efficacy without compliance concerns.

Multidisciplinary Care Coordination

Optimal outcomes require coordination between rheumatology, obstetrics, anesthesiology, and neonatology. Establish clear communication channels and shared decision-making processes.

Document detailed care plans in shared medical records including:

• Current and planned medications with rationale
• Disease activity trends
• Pregnancy complications or risk factors
• Delivery planning considerations
• Postpartum medication strategy
• Lactation plans

Hack: Create a one-page "pregnancy summary sheet" updated at each visit listing current medications, disease activity status, pregnancy complications, and key management decisions. This facilitates communication with all team members and emergency providers.

Conclusion

Managing rheumatoid arthritis during pregnancy and lactation requires synthesizing complex pharmacological data, understanding pregnancy-related immunological changes, and individualizing care to each patient's unique circumstances. Successful outcomes depend upon meticulous preconception planning, close monitoring throughout gestation and the postpartum period, evidence-based medication selection, and multidisciplinary collaboration. By following the systematic approach outlined in this review, internists can confidently guide patients through this challenging but manageable clinical scenario, optimizing both maternal disease control and fetal outcomes.

Key Takeaway Pearls

1. Achieve disease remission or low activity for 3-6 months before conception
2. Certolizumab pegol is the biologic of choice during pregnancy
3. The postpartum period carries highest flare risk—restart medications immediately
4. Hydroxychloroquine is safe and should be continued throughout
5. Most RA medications compatible with pregnancy are also compatible with lactation
6. Screen all patients for anti-Ro/SSA and antiphospholipid antibodies
7. Morning stiffness improves most reliably during pregnancy
8. Cervical spine imaging is needed before intubation in severe, longstanding disease

References

1. Götestam Skorpen C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.

2. Sammaritano LR, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72(4):529-556.

3. Clowse MEB, et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52(2):514-521.

4. de Man YA, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008;59(9):1241-1248.

5. Mariette X, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233.

6. Ostensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5(7):382-390.

7. Kavanaugh A, et al. Certolizumab pegol in pregnant patients with chronic inflammatory diseases: updated interim data from a prospective, long-term exposure registry. Arthritis Rheumatol. 2017;69(suppl 10).

8. Flint J, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016;55(9):1693-1697.

9. Barrett JH, et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom. Arthritis Rheum. 1999;42(6):1219-1227.

10. Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Rev Clin Immunol. 2016;12(9):937-944.

---

Word count: 2,000